Anti-infective Agents
Certain bacterial, protozoal, and viral infections remain the most frequent infectious diseases causing morbidity and death globally. However, the development of new drugs for the treatment of such infectious diseases has been slow, although some promising drugs have been developed and used for clinical control of such intractable infections. For example, antiviral drugs, including remdesivir and favipiravir, are currently used for the clinical treatment of coronavirus disease 2019 (COVID-19) patients. Notably, these drugs have been developed based on the drug repositioning technique. In addition, some immune-regulatory drugs, including corticosteroids, baricitinib and tocilizumab, help reduce inflammation in the body since inflammation can lead to some of the more severe symptoms of COVID-19 patients. However, at present, we have substantially no new drugs, which act on metabolic reactions by specifically inhibiting viral proteins of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in host cells. Only recombinant antibodies specific to spike proteins of the coronavirus, such as bamlanivimab, etesevimab, casirivimab, and imdevimab, have been approved or are in the development for clinical use as immune-adjunctive treatment of COVID-19 patients with mild symptoms. In this context, the drug design based on quantitative structureactivity relationship (QSAR) analysis, especially three-dimensional-QSAR, may be very beneficial for the development of SARS-CoV-2- specific chemotherapeutic anti-infective agents [1]. ...